Amplia Therapeutics Limited
OTC: INNMF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher J. Burns
- Employees
- 1
- Headquarters
- Melbourne, Australia
- IPO year
- 2021
- Market cap
- $41.1M
- Website
- https://www.ampliatx.com
Loading INNMF…
Loading profile data…Frequently asked questions about INNMF
What does Amplia Therapeutics Limited (INNMF) do?
Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes A...
Where does INNMF trade?
Amplia Therapeutics Limited (INNMF) trades on the Other OTC.
What sector is INNMF in?
Amplia Therapeutics Limited (INNMF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Amplia Therapeutics Limited?
Christopher J. Burns is the chief executive officer of Amplia Therapeutics Limited (INNMF).
Where is Amplia Therapeutics Limited headquartered?
Amplia Therapeutics Limited is headquartered in Australia.
Does INNMF pay a dividend?
Amplia Therapeutics Limited (INNMF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INNMF go public?
Amplia Therapeutics Limited (INNMF) completed its initial public offering in 2021.